A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer

NCT07678957 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: BL-M07D1
DRUG: DS-8201

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]